查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004915

被忽视的热带疾病诊断市场：按技术、疾病类型和最终用户划分－2026-2032年全球预测

Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

被忽视的热带疾病诊断市场预计到 2025 年将达到 74.7 亿美元，到 2026 年将成长到 79.4 亿美元，到 2032 年将达到 112.7 亿美元，复合年增长率为 6.05%。

主要市场统计数据
基准年 2025 74.7亿美元
预计年份：2026年 79.4亿美元
预测年份 2032 112.7亿美元
复合年增长率 (%) 6.05%

对被忽视的热带疾病的诊断进行背景解释，将其置于全球卫生优先事项和实际情况的背景下，以便指南战略决策。

被忽视的热带疾病（NTDs）在许多中低收入国家仍然是持续存在的公共卫生挑战，为卫生系统和发展伙伴带来了复杂的诊断难题。 NTDs的诊断策略必须在敏感性和特异性需求与基础设施、人力资源能力和供应链韧性等限制因素之间取得平衡。随着全球卫生相关人员转向疾病综合管理和根除目标，诊断正变得至关重要，它既是进行临床诊疗的手段，也是计画决策的监测工具。

对不同卫生系统中被忽视的热带疾病诊断的关键技术、监管、规划和采购变化进行分析。

由于技术、计画和政策等多方面因素的共同作用，被忽视的热带疾病（NTD）的诊断格局正在经历多项变革。分子生物学的创新、仪器的微型化以及数位连接的普及降低了部分技术壁垒，使得在分散的环境中也能进行更灵敏的检测。同时，人们越来越重视支持多病种筛检和监测的综合诊断，这反映了医疗保健系统向更高效的模式和资源优化转型的大趋势。

本文探讨了贸易政策和关税压力的变化如何改变诊断设备的筹资策略、供应链的韧性以及专案永续性。

近期主要市场贸易政策和关税结构的变化为诊断供应链带来了新的成本考量，影响试剂、耗材和诊断硬体的筹资策略。进口关税和海关程序的变化不仅会影响到货成本，还会影响采购週期的灵活性。这在需要快速扩大专案规模时至关重要，例如应对感染疾病疫情或大规模药物管理宣传活动。关税法规与区域生产能力之间的相互作用是供应商决定生产本地化和库存储存地点的关键因素。

基于全面细分的洞察，将诊断技术、疾病特定需求、最终用户背景、应用和检体类型与部署优先事项关联起来。

对技术、疾病类型、最终用户、应用和检体类型等细分市场的深入理解，揭示了创新和推广的清晰路径。在技​​术领域，免疫检测（包括化学冷光和酵素免疫分析法(ELISA)）在血清学监测和确诊检测中仍然发挥着重要作用，而显微镜技术（包括萤光和光学显微镜）在许多情况下仍然是低成本诊断的基础手段。分子诊断技术，例如聚合酵素链锁反应(PCR) 和等温扩增，对低寄生虫负荷的感染疾病具有高灵敏度，并在确诊过程中发挥越来越重要的作用。快速诊断测试（包括抗原检测和抗体检测）为社区筛检和临床决策提供了所需的便利性和速度。

美洲、欧洲、中东和非洲以及亚太地区的规划和营运趋势决定了诊断的取得和实施方案。

区域趋势持续影响专案优先事项、诊断获取途径和产品部署路径。在美洲，都市区差距以及局部流行区的存在，使得将三级医疗机构的实验室诊断能力与远距快速筛检工具相结合成为推广，重点在于将被忽视的热带疾病（NTD）诊断纳入更广泛的基层医疗服务。跨境合作和地方公共卫生倡议正在影响集中采购和数据共用实践，以支持有针对性的根除计划。

深入了解被忽视的热带疾病 (NTD) 诊断领域的竞争格局、合作伙伴关係和产品差异化策略。

被忽视的热带疾病（NTD）诊断领域的竞争格局由成熟的诊断公司、专注于特定领域的研发公司、学术实验室以及支持检验和临床评估的受託研究机构组成。成熟公司正在调整其产品组合，以满足对整合检测解决方案和数位化连接的需求，而小规模的创新者则倾向于专注于颠覆性平台，例如简化的等温扩增、新型抗原检测化学以及专为现场部署而设计的无需仪器的读取器。

为製造商、资助者和专案规划者提供实用建议，使诊断技术的创新与现场部署和专案永续性。

产业领导者应采取务实且多管齐下的方法，使创新与实际部署相契合。首先，优先发展稳健、易用且最大限度减少对复杂低温运输和精密基础设施依赖的研发路径，从而扩大诊断技术有效部署的环境范围。其次，投资进行检验研究，以证明其在专案实施环境中以及所有相关检体类型中的表现，从而建立采购机构和第一线医护人员的信任。

为了支持所提出的研究结果，我们将清楚地解释混合方法研究途径，该方法结合了相关人员访谈、文献整合和比较分析。

本报告整合了一手和二手研究资料，结合相关人员访谈、产品性能文献、监管指导文件和实地检验研究，对研究结果进行了多角度的检验。一手资料包括对诊断方法开发人员、实验室管理人员、流行地区临床医生、采购专家和公共卫生专案管理人员的结构化访谈，这些访谈提供了关于可用性、供应链考量和推广障碍的定性观点。二手资料包括关于诊断性能的同行评审文献、公开的监管标准以及全球卫生当局关于实施被忽视的热带病（NTD）项目的技术指导。

策略结论强调可操作的创新、伙伴关係以及采购系统的调整，以此作为改善诊断技术和永续公共卫生成果的途径。

诊断技术在推动被忽视的热带疾病（NTD）防治工作中发挥核心作用，对个别患者照护和人群层面的计画目标均有贡献。技术进步、采购惯例的转变以及对监测日益重视，为弥合数十年来诊断方面的差距创造了契机。为了充分发挥这一潜力，研发人员、资助者、专案实施者和监管机构必须携手合作，确保产品从实用化走向实际应用，同时优先考虑易用性、品质和供应链的韧性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：被忽视的热带疾病诊断市场：依技术划分

  • 免疫检测
    • 化学冷光
    • 酵素免疫分析法
  • 显微镜检查
    • 萤光显微镜
    • 光学显微镜
  • 分子诊断
    • 等温扩增
    • 聚合酵素链锁反应
  • 快速诊断测试
    • 抗体检测
    • 抗原检测

第九章：被忽视的热带疾病诊断市场：依疾病类型划分

  • 南美锥虫病
    • 酵素免疫分析法
    • 聚合酵素链锁反应
  • 利什曼原虫症
    • 皮肤利什曼原虫症检测
    • 利什曼原虫症检测
  • 淋巴丝虫病
    • 抗体检测
    • 层析法
  • 盘尾丝虫病
    • 聚合酵素链锁反应
    • 皮肤SNI显微镜
  • 血吸虫病
    • 粪便显微镜检查
    • 尿抗原检测

第十章：被忽视的热带疾病诊断市场：以最终用户划分

  • 诊所
    • 社区健康中心
    • 基层医疗诊所
  • 诊断检查室
    • 独立检测实验室
    • 测试承包组织
  • 医院
    • 私立医院
    • 公立医院
  • 研究机构

第十一章：被忽视的热带疾病诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：被忽视的热带疾病诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：被忽视的热带疾病诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国被忽视的热带疾病诊断市场

第十五章：中国被忽视的热带疾病诊断市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Anitoa Systems, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Coris BioConcept SPRL
  • DiaSys Diagnostic Systems GmbH
  • F. Hoffmann-La Roche Ltd
  • Genome Diagnostics Pvt. Ltd.
  • Hologic, Inc.
  • InBios International, Inc.
  • Johnson & Johnson Services, Inc.
  • Meridian Bioscience, Inc.
  • Novartis AG
  • Omega Diagnostics Group plc
  • Oscar Medicare Pvt. Ltd.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • ZeptoMetrix Corporation
Product Code: MRR-742BD5181EB6

The Neglected Tropical Diseases Diagnosis Market was valued at USD 7.47 billion in 2025 and is projected to grow to USD 7.94 billion in 2026, with a CAGR of 6.05%, reaching USD 11.27 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.47 billion
Estimated Year [2026] USD 7.94 billion
Forecast Year [2032] USD 11.27 billion
CAGR (%) 6.05%

Contextual introduction that situates neglected tropical diseases diagnostics within global health priorities and operational realities to guide strategic decision making

Neglected tropical diseases (NTDs) remain a persistent public health challenge in many low- and middle-income settings, placing complex diagnostic demands on health systems and development partners. Diagnostic strategies for NTDs must reconcile the need for sensitivity and specificity with constraints in infrastructure, workforce capacity, and supply chain resilience. As global health actors pivot toward integrated disease management and elimination goals, diagnostics assume a central role both as enablers of clinical care and as surveillance instruments for programmatic decision-making.

This executive summary synthesizes current diagnostic technology trends, disease-specific testing pathways, end-user dynamics, and regional programmatic drivers that shape the evolving landscape. The intent is to provide healthcare leaders, diagnostic developers, procurement agencies, and policy makers with a concise yet comprehensive analytical foundation to support strategic planning. By framing diagnostic innovation alongside operational realities, the summary highlights where technological advances, policy shifts, and financing mechanisms intersect to accelerate-or in some cases impede-progress against NTDs.

The content emphasizes practical implications for stakeholders who must balance diagnostic performance with affordability, accessibility, and sustainability. It also underscores the interplay between point-of-care approaches and centralized laboratory confirmation, illustrating how diverse testing modalities contribute differently to case detection, surveillance, and program validation across varied epidemiological contexts.

Analysis of the pivotal technological, regulatory, programmatic, and procurement shifts reshaping diagnostics for neglected tropical diseases across diverse health systems

The diagnostic landscape for NTDs is undergoing several transformative shifts driven by converging technological, programmatic, and policy forces. Innovations in molecular biology, miniaturized instrumentation, and digital connectivity have lowered some technical barriers, enabling more sensitive assays to be used in decentralized settings. At the same time, there is an increasing emphasis on integrated diagnostics that support multi-disease screening and surveillance, reflecting a broader push for health system efficiencies and resource optimization.

Regulatory evolution and quality assurance frameworks are also reshaping product pathways. Greater attention to validation in real-world contexts, along with calls for harmonized performance standards, is prompting manufacturers and developers to design assays that meet both laboratory and point-of-care expectations. Procurement behaviors are shifting toward outcome-based and pooled purchasing mechanisms, encouraging suppliers to align product portfolios with programmatic needs rather than purely laboratory-driven specifications.

Operationally, community-level programs are demanding tests that are rapid, robust under field conditions, and deliver clear actionable outputs for frontline workers. Simultaneously, centralized laboratories continue to require high-throughput, confirmatory platforms to validate cases and support elimination verification. These dual imperatives are driving hybrid strategies that pair on-site screening with confirmatory laboratory workflows, supported by digital reporting chains that enable faster public health action and improved surveillance granularity.

Examination of how evolving trade policies and tariff pressures are altering diagnostic sourcing strategies, supply chain resilience, and procurement trade-offs for program sustainability

Recent shifts in trade policy and tariff structures in major markets have introduced new cost considerations into diagnostic supply chains, affecting sourcing strategies for reagents, consumables, and diagnostic hardware. Changes to import duties and customs practices can influence not only landed costs but also the agility of procurement cycles, which are critical when programs require rapid scale-up during outbreak responses or mass drug administration campaigns. The interplay between tariff rules and regional manufacturing capacity has become an important determinant of where suppliers choose to localize production or stock inventory.

For program planners and procurement officers, the practical implication is a reassessment of supplier portfolios and an increased focus on supply chain redundancy. Organizations are evaluating the trade-offs between single-source procurement of validated products and diversified sourcing that mitigates tariff-driven price volatility or border-related delays. In some cases, increased tariffs have accelerated conversations about regional manufacturing partnerships and technology transfer models that can insulate programs from future policy shocks.

Operationally, tariff-induced cost pressures tend to magnify the advantage of diagnostic approaches that minimize recurring imports, such as assays with longer shelf-lives, reduced cold-chain dependence, or platforms compatible with locally produced consumables. As a result, stakeholders are reexamining test selection criteria with supply chain resilience and total cost of ownership in mind, favoring solutions that balance diagnostic performance with pragmatic logistics under evolving trade conditions.

Comprehensive segmentation-driven insights that map diagnostic technologies, disease-specific needs, end-user contexts, applications, and sample types to implementation priorities

A nuanced understanding of segmentation across technology, disease type, end user, application, and sample type reveals distinct pathways for innovation and implementation. In the technology domain, immunoassays-encompassing chemiluminescence assays and enzyme-linked immunosorbent assays-remain important for serological surveillance and confirmatory testing, while microscopy approaches, including fluorescence and light microscopy, continue to serve as low-cost diagnostic backbones in many settings. Molecular diagnostics, represented by polymerase chain reaction and isothermal amplification methods, offer high sensitivity for low-parasite-burden infections and play an increasingly central role in confirmation workflows. Rapid diagnostic tests, with both antigen and antibody detection formats, provide the speed and simplicity required for community screening and point-of-care decision-making.

Disease-specific diagnostics show differentiated needs that shape product development and deployment. Chagas diagnostics frequently pair enzyme-linked immunosorbent assay and polymerase chain reaction to address both chronic serology and acute parasitemia detection, whereas leishmaniasis diagnostics bifurcate into tests optimized for cutaneous and visceral presentations. Lymphatic filariasis relies heavily on antibody detection tests alongside immunochromatographic approaches for mass screening, while onchocerciasis often requires polymerase chain reaction and skin snip microscopy methods depending on program stage. Schistosomiasis testing strategies blend stool microscopy concentration techniques with urine antigen assays to accommodate community-level mapping and individual case confirmation.

End-user contexts strongly influence acceptable product attributes. Clinics and primary care settings prioritize ease of use and minimal infrastructure requirements, community health centers need durable tests suited for outreach, diagnostic laboratories demand standardized protocols and traceability, and hospitals-both private and public-require integration with clinical workflows and laboratory information systems. Research institutes further drive innovation by evaluating novel biomarkers and validation protocols. Applications range from confirmatory laboratory and point-of-care confirmation to community screening approaches that support mass drug administration, and surveillance activities that span epidemiological monitoring through to post-elimination vigilance. Sample type considerations-blood in serum, plasma or whole blood formats, stool through concentration or direct smear, tissue from biopsies or skin snips, and urine via concentrated or direct testing-determine pre-analytical workflows and influence test design choices such as input volumes, preservation requirements, and biosafety implications.

Taken together, segmentation insights highlight where manufacturers can differentiate offerings by aligning technology platforms with disease-specific performance needs, by tailoring workflows to end-user capacity, and by optimizing sample handling to suit programmatic realities. This segmentation-driven lens helps stakeholders prioritize investments that close diagnostic gaps while ensuring practical deployability across diverse operational environments.

Regional programmatic and operational dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine diagnostic access and implementation choices

Regional dynamics continue to shape programmatic priorities, diagnostic accessibility, and product adoption pathways. In the Americas, urban-rural disparities and pockets of endemicity require a blend of laboratory confirmation capacity in tertiary centers and rapid screening tools for remote outreach, with an emphasis on integrating NTD diagnostics into broader primary care services. Cross-border coordination and regional public health initiatives influence procurement harmonization and data sharing practices that support targeted elimination programs.

Europe, Middle East & Africa presents a heterogeneous landscape where some countries possess advanced laboratory infrastructure while others face significant resource constraints. This region's priorities often include strengthening laboratory networks, building quality assurance systems, and enabling decentralized diagnostics that can function with intermittent power and limited cold-chain capacity. Regulatory environments and fragmented procurement mechanisms in parts of the region make harmonized validation and pooled purchasing attractive options for reducing duplicative costs and improving access.

Asia-Pacific exhibits a wide spectrum of epidemiological contexts, from densely populated urban centers to remote island communities. Program strategies here emphasize scalable screening modalities, integration with other endemic disease programs, and investments in local manufacturing capacity to shorten supply chains. The region's growing diagnostic manufacturing footprint and increasing public-private collaboration present opportunities to adapt technologies for both high-volume surveillance and sensitive case confirmation in low-transmission settings.

Insights into the competitive landscape, collaborative partnerships, and product differentiation strategies shaping the neglected tropical diseases diagnostics sector

The competitive ecosystem for NTD diagnostics includes a mix of established diagnostics manufacturers, specialized niche developers, academic laboratories, and contract research organizations that support validation and clinical evaluation. Established firms are adapting portfolios to address the need for integrated testing solutions and digital connectivity, while smaller innovators often focus on disruptive platforms such as simplified isothermal amplification, novel antigen detection chemistries, and instrument-free readouts designed for field deployment.

Collaborations between commercial entities and academic research centers accelerate translation of novel biomarkers into deployable assays, and partnerships with non-governmental organizations and global health donors help pilot products in real-world program settings. Contract development and manufacturing organizations play a critical role in scaling production and ensuring quality systems compliance, particularly for late-stage validation and prequalification. Procurement entities increasingly expect suppliers to demonstrate robust post-market surveillance and support mechanisms for training, quality control, and supply continuity.

For companies seeking to differentiate, investment in usability testing, end-user training materials, and digital integration capabilities can create competitive advantage. Similarly, strategic alliances that enable regional manufacturing or in-country assembly can mitigate supply chain disruption and improve access in markets where localization reduces logistical friction and supports program sustainability.

Actionable recommendations for manufacturers, funders, and program planners to align diagnostic innovation with field deployment realities and program sustainability

Industry leaders should adopt a pragmatic, multi-pronged approach that aligns innovation with implementation realities. First, prioritize development pathways that emphasize robustness, ease of use, and minimal reliance on complex cold chains or sophisticated infrastructure, thereby expanding the range of settings where diagnostics can be effectively deployed. Second, invest in validation studies that demonstrate performance in programmatic conditions and across relevant sample types to build confidence among procurement agencies and frontline providers.

Third, cultivate regional manufacturing or assembly partnerships to reduce exposure to cross-border trade disruptions and to shorten lead times for consumables and instruments. Fourth, design pricing and distribution models that reflect the total cost of ownership, including training, quality assurance, and maintenance, and engage early with procurement stakeholders to align product specifications with program budgets and policy frameworks. Fifth, incorporate digital reporting capabilities that streamline data flows from peripheral testing sites to central surveillance systems, enabling faster public health responses and more efficient program monitoring.

Finally, adopt collaborative commercialization strategies that include partnerships with non-governmental organizations, governmental programs, and research institutes to facilitate field evaluations, user feedback loops, and phased roll-outs that inform product iteration. By executing on these priorities, industry leaders can ensure that investments in technology translate into measurable improvements in case detection, surveillance quality, and programmatic impact.

Clear explanation of the mixed-methods research approach combining stakeholder interviews, literature synthesis, and comparative analysis to underpin the insights presented

This report synthesizes primary and secondary research, combining stakeholder interviews, product performance literature, regulatory guidance documents, and field validation studies to triangulate insights. Primary inputs include structured interviews with diagnostic developers, laboratory directors, clinicians in endemic settings, procurement specialists, and public health program managers, which provided qualitative perspectives on usability, supply chain considerations, and adoption barriers. Secondary sources comprised peer-reviewed literature on diagnostic performance, publicly available regulatory standards, and technical guidance from global health authorities related to NTD program implementation.

Analytical methods included cross-segmentation mapping to identify alignment and gaps between technology attributes and end-user needs, scenario analysis to assess supply chain and procurement sensitivities, and comparative assessment of diagnostic workflows across disease-specific contexts. Where available, real-world validation data and field study outcomes informed assessments of operational suitability. The methodology prioritized transparency by documenting data provenance, interview protocols, and criteria used for technology and product evaluation, enabling reproducibility and informed follow-up research.

Limitations include variability in published performance data across settings and the evolving nature of regulatory pathways, which require ongoing monitoring. Nonetheless, the mixed-methods approach provides a robust foundation for strategic decision-making by combining empirical evidence with practical stakeholder perspectives drawn from diverse geographic and institutional contexts.

Strategic conclusion emphasizing pragmatic innovation, partnerships, and procurement alignment as the pathway to improved diagnostics and durable public health gains

Diagnostics are central to progress against neglected tropical diseases, serving both individual patient care and population-level program objectives. The convergence of technological advances, shifting procurement practices, and heightened emphasis on surveillance creates a window of opportunity to close diagnostic gaps that have persisted for decades. Realizing this potential requires coordinated action across developers, funders, program implementers, and regulatory bodies to ensure that products move from innovation to deployment with attention to usability, quality, and supply chain resilience.

Strategic investments in regionally appropriate technologies, validation in programmatic contexts, and mechanisms that de-risk local manufacturing will accelerate access and sustainability. Moreover, integrated approaches that combine rapid screening at the community level with confirmatory laboratory workflows and strengthened data systems will enhance detection sensitivity while supporting timely public health interventions. The cumulative effect of these steps will be measurable improvements in case finding, surveillance fidelity, and the ability to validate elimination milestones in endemic regions.

Ultimately, the path forward is one of pragmatic innovation: technologies that meet field realities, partnerships that bridge development and delivery, and procurement strategies that emphasize reliability and total cost considerations. Stakeholders who align their initiatives with these principles will be best positioned to translate diagnostic advances into durable public health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neglected Tropical Diseases Diagnosis Market, by Technology

  • 8.1. Immunoassays
    • 8.1.1. Chemiluminescence Assay
    • 8.1.2. Enzyme Linked Immunosorbent Assay
  • 8.2. Microscopy
    • 8.2.1. Fluorescence Microscopy
    • 8.2.2. Light Microscopy
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. Polymerase Chain Reaction
  • 8.4. Rapid Diagnostic Tests
    • 8.4.1. Antibody Detection
    • 8.4.2. Antigen Detection

9. Neglected Tropical Diseases Diagnosis Market, by Disease Type

  • 9.1. Chagas Disease
    • 9.1.1. Enzyme Linked Immunosorbent Assay
    • 9.1.2. Polymerase Chain Reaction
  • 9.2. Leishmaniasis
    • 9.2.1. Cutaneous Leishmaniasis Tests
    • 9.2.2. Visceral Leishmaniasis Tests
  • 9.3. Lymphatic Filariasis
    • 9.3.1. Antibody Detection Test
    • 9.3.2. Immunochromatographic Test
  • 9.4. Onchocerciasis
    • 9.4.1. Polymerase Chain Reaction
    • 9.4.2. Skin Snip Microscopy
  • 9.5. Schistosomiasis
    • 9.5.1. Stool Microscopy
    • 9.5.2. Urine Antigen Test

10. Neglected Tropical Diseases Diagnosis Market, by End User

  • 10.1. Clinics
    • 10.1.1. Community Health Centers
    • 10.1.2. Primary Care Clinics
  • 10.2. Diagnostic Laboratories
    • 10.2.1. Independent Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals
  • 10.4. Research Institutes

11. Neglected Tropical Diseases Diagnosis Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Neglected Tropical Diseases Diagnosis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Neglected Tropical Diseases Diagnosis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Neglected Tropical Diseases Diagnosis Market

15. China Neglected Tropical Diseases Diagnosis Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Agilent Technologies, Inc.
  • 16.7. Anitoa Systems, Inc.
  • 16.8. Becton, Dickinson and Company
  • 16.9. bioMerieux SA
  • 16.10. Coris BioConcept SPRL
  • 16.11. DiaSys Diagnostic Systems GmbH
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. Genome Diagnostics Pvt. Ltd.
  • 16.14. Hologic, Inc.
  • 16.15. InBios International, Inc.
  • 16.16. Johnson & Johnson Services, Inc.
  • 16.17. Meridian Bioscience, Inc.
  • 16.18. Novartis AG
  • 16.19. Omega Diagnostics Group plc
  • 16.20. Oscar Medicare Pvt. Ltd.
  • 16.21. QIAGEN N.V.
  • 16.22. Siemens Healthineers AG
  • 16.23. Thermo Fisher Scientific Inc.
  • 16.24. ZeptoMetrix Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS